{
    "clinical_study": {
        "@rank": "166499", 
        "arm_group": [
            {
                "arm_group_label": "MEHD7945A+ Cisplatin + 5-FU", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "MEHD7945A + Paclitaxel + Carboplatin", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This open-label, multicenter study will evaluate the safety, pharmacokinetics an d antitumor\n      activity of MEHD7945A in patients with recurrent/metastatic squamous cell carcinoma of the\n      head and neck. Patients will receive MEHD7945A intravenou sly every 3 weeks in combination\n      with a maximum of 6 cycles of either cisplatin plus 5-FU or carboplatin plus paclitaxel.\n      Anticipated time on study treatment is until disease progression or unacceptable toxicity\n      occurs."
        }, 
        "brief_title": "A Study of MEHD7945A in Combination With Cisplatin and 5-FU or Paclitaxel and Carboplatin on Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Head and Neck Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Head and Neck Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed recurrent or metastatic squamous cell carcinoma of the head\n             and neck (SCCHN) of mucosal origin (e.g., oral cavity, oropharynx, hypopharynx,\n             larynx) that is not amenable to further curative local therapy (e.g., surgery,\n             radiation including re-irradiation) (1L R/M)\n\n          -  Patients with unknown primary SCCHN presumed to be of head and neck mucosal origin\n             are eligible if they meet all other entry criteria.\n\n          -  For patients who present with de novo metastatic disease, no prior systemic\n             chemotherapy is allowed.\n\n          -  For patients with recurrent SCCHN, prior systemic therapy is allowed if it was given\n             as part of their definitive therapy. If patients have received prior combined\n             chemo-radiation therapy, they must be off therapy for at least 3 months.\n\n          -  Consent to provide archival tumor tissue for biomarker testing\n\n          -  Life expectancy >/= 12 weeks\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of  0, 1, or 2\n\n          -  Disease that is measurable per modified RECIST v1.1\n\n          -  Adequate bone marrow and organ function\n\n        Exclusion Criteria:\n\n          -  Nasopharyngeal cancer\n\n          -  Prior treatment with an investigational or approved agent for the purpose of\n             inhibiting HER family members\n\n               -  This includes, but is not limited to, cetuximab, panitumumab, erlotinib,\n                  gefitinib, and lapatinib.\n\n               -  Prior treatment with an EGFR inhibitor is allowed if it was administered as part\n                  of definitive therapy for locally advanced disease and completed/terminated >/=\n                  3 months before study enrollment.\n\n          -  Major surgical procedure within 4 weeks prior to Day 1\n\n          -  Leptomeningeal disease as the only manifestation of the current malignancy\n\n          -  Active infection requiring antibiotics\n\n          -  Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory\n             drugs (NSAIDs)\n\n          -  Symptomatic hypercalcemia requiring continued use of bisphosphonate therapy\n\n          -  Current severe, uncontrolled systemic disease\n\n          -  History of cardiac heart failure of New York Heart Association Class II or greater or\n             serious cardiac arrhythmia requiring treatment (except for atrial fibrillation and\n             paroxysmal supraventricular tachycardia)\n\n          -  History of myocardial infarction within 6 months prior to Cycle 1, Day 1, or history\n             of unstable angina\n\n          -  Clinically significant history of liver disease, including viral or other hepatitis,\n             current alcohol abuse, or cirrhosis\n\n          -  History of bleeding diathesis or coagulopathy other than that due to anticoagulation\n             therapy\n\n          -  Clinically significant GI bleeding within 6 months prior to Cycle 1, Day 1\n\n          -  History of ILD\n\n          -  History of severe (Grade 3 or 4) allergic or hypersensitivity reaction to therapeutic\n             antibodies that required discontinuation of therapy\n\n          -  Known human immunodeficiency virus (HIV) infection\n\n          -  Untreated/active CNS metastases (progressing or requiring anticonvulsants or\n             corticosteroids for symptomatic control)\n\n          -  Pregnancy (positive pregnancy test) or lactation\n\n          -  Malignancies other than SCCHN within 5 years prior to randomization, with the\n             exception of adequately treated basal or squamous cell skin cancer and carcinoma in\n             situ of the cervix or skin (e.g., melanoma in situ)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01911598", 
            "org_study_id": "GO28909", 
            "secondary_id": "2013-001285-42"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "MEHD7945A+ Cisplatin + 5-FU", 
                    "MEHD7945A + Paclitaxel + Carboplatin"
                ], 
                "description": "IV Day 1 every 3 weeks", 
                "intervention_name": "MEHD7945A", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MEHD7945A+ Cisplatin + 5-FU", 
                "description": "100 mg/m2 IV Day 1 every 3 weeks, up to 6 cycles", 
                "intervention_name": "cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MEHD7945A+ Cisplatin + 5-FU", 
                "description": "1000 mg/m2 IV Days 1-4 every 3 weeks, up to 6 cycles", 
                "intervention_name": "5-FU", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MEHD7945A + Paclitaxel + Carboplatin", 
                "description": "AUC=6 mg/mL/min IV Day 1 every 3 weeks, up to 6 cycles", 
                "intervention_name": "carboplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MEHD7945A + Paclitaxel + Carboplatin", 
                "description": "200 mg/m2 IV Day 1 every 3 weeks, up to 6 cycles", 
                "intervention_name": "paclitaxel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cisplatin", 
                "Fluorouracil", 
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bruxelles", 
                        "country": "Belgium", 
                        "zip": "1200"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edegem", 
                        "country": "Belgium", 
                        "zip": "2650"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "3000"
                    }
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1b Open-Label Study of the Safety and Pharmacokinetics of MEHD7945A in Combination With Either Cisplatin and 5-FU or Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: GO28909 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Genentech", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 28 months"
            }, 
            {
                "measure": "Incidence and nature of dose-limiting toxicities", 
                "safety_issue": "Yes", 
                "time_frame": "21 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01911598"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics: Area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "15 days"
            }, 
            {
                "measure": "Pharmacokinetics: Serum concentrations (Cmax/Cmin)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Cisplatin pharmacokinetics: Area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 6 hours post-dose"
            }, 
            {
                "measure": "5-FU pharmacokinetics: Area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 24 hours post-dose"
            }, 
            {
                "measure": "Carboplatin pharmacokinetics: Area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 6 hours post-dose"
            }, 
            {
                "measure": "Paclitaxel pharmacokinetics: Area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 24 hours post-dose"
            }, 
            {
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "approximately 24 months"
            }, 
            {
                "measure": "Disease control rate", 
                "safety_issue": "No", 
                "time_frame": "approximately 24 months"
            }, 
            {
                "measure": "Duration of objective response", 
                "safety_issue": "No", 
                "time_frame": "approximately 24 months"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "approximately 24 months"
            }
        ], 
        "source": "Genentech", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}